Diagnostic accuracy of miRNAs as potential biomarkers for systemic lupus erythematosus: a meta-analysis

[1]  T. Mimori,et al.  Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC) , 2018, Modern rheumatology.

[2]  X. Xue,et al.  Detection of the plasma miR-92a expression in systemic lupus erythematosus and its clinic significance , 2017 .

[3]  G. Burmester,et al.  What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. , 2017, Clinical and experimental rheumatology.

[4]  T. Motawi,et al.  MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus. , 2016, Chemico-biological interactions.

[5]  H. Lorenzi,et al.  High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus , 2016, PloS one.

[6]  C. Tani,et al.  One year in review 2016: systemic lupus erythematosus. , 2016, Clinical and experimental rheumatology.

[7]  J. Craig,et al.  Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines , 2015, Arthritis care & research.

[8]  J. Post,et al.  MicroRNA Levels as Prognostic Markers for the Differentiation Potential of Human Mesenchymal Stromal Cell Donors. , 2015, Stem cells and development.

[9]  E. Gamazon,et al.  MicroRNA biogenesis and cellular proliferation. , 2015, Translational research : the journal of laboratory and clinical medicine.

[10]  Matthias Schneider,et al.  The Diagnosis and Treatment of Systemic Lupus Erythematosus. , 2015, Deutsches Arzteblatt international.

[11]  Meng Li,et al.  Circulating MicroRNAs: Potential and Emerging Biomarkers for Diagnosis of Cardiovascular and Cerebrovascular Diseases , 2015, BioMed research international.

[12]  D. Hoon,et al.  A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients , 2015, Oncotarget.

[13]  D. Kamen.  Environmental influences on systemic lupus erythematosus expression. , 2014, Rheumatic diseases clinics of North America.

[14]  Gang Pan,et al.  Expression Profile and Clinical Significance of MicroRNAs in Papillary Thyroid Carcinoma , 2014, Molecules.

[15]  P. Ahmadpoor,et al.  An update on pathogenesis of systemic lupus erythematosus. , 2014, Iranian journal of kidney diseases.

[16]  Li-hua Hu,et al.  Clinical Relevance of Plasma miR‐21 in New‐Onset Systemic Lupus Erythematosus Patients , 2014, Journal of clinical laboratory analysis.

[17]  Cong Yu,et al.  Diagnostic criteria for systemic lupus erythematosus: a critical review. , 2014, Journal of autoimmunity.

[18]  H. Mann,et al.  Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[19]  Ruedi Aebersold,et al.  Timescales and bottlenecks in miRNA-dependent gene regulation , 2013, Molecular systems biology.

[20]  T. Ochiya,et al.  Roles of micrornas in the Hepatitis B Virus Infection and Related Diseases , 2013, Viruses.

[21]  E. Van Obberghen,et al.  MicroRNAs and metabolism crosstalk in energy homeostasis. , 2013, Cell metabolism.

[22]  H. Anders,et al.  The pathogenesis of lupus nephritis. , 2013, Journal of the American Society of Nephrology : JASN.

[23]  N. Lai,et al.  Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis , 2013, Clinical and experimental immunology.

[24]  W. Louthrenoo,et al.  Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: a comparison using control sera obtained from healthy individuals and patients with multiple medical problems. , 2013, Asian Pacific journal of allergy and immunology.

[25]  K. Ghosh,et al.  Clinical and immunological profile of systemic lupus erythematosus , 2013, Indian Pediatrics.

[26]  Thomas Tuschl,et al.  Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations , 2013, Proceedings of the National Academy of Sciences.

[27]  Swati Suryawanshi,et al.  Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer , 2013, Clinical Cancer Research.

[28]  L. Pinto,et al.  [Systemic lupus erythematosus and pregnancy]. , 2013, Acta medica portuguesa.

[29]  Jin-Young Choi,et al.  The pathogenesis of systemic lupus erythematosus-an update. , 2012, Current opinion in immunology.

[30]  J. Mendell,et al.  MicroRNAs in Stress Signaling and Human Disease , 2012, Cell.

[31]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[32]  Alicia Algeciras-Schimnich,et al.  Analysis of circulating microRNA: preanalytical and analytical challenges. , 2011, Clinical chemistry.

[33]  R. Place,et al.  miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells , 2010, Oncotarget.

[34]  Oliver Distler,et al.  MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. , 2010, Arthritis and rheumatism.

[35]  Kaleb M. Pauley,et al.  MicroRNA in autoimmunity and autoimmune diseases. , 2009, Journal of autoimmunity.

[36]  Patrick Bossuyt,et al.  Systematic Reviews of Diagnostic Test Accuracy , 2008, Annals of Internal Medicine.

[37]  Kaleb M. Pauley,et al.  Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients , 2008, Arthritis research & therapy.

[38]  P. Angchaisuksiri,et al.  Specificity and sensitivity of anti-β2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome , 2007, Clinical Rheumatology.

[39]  J Shepherd,et al.  Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. , 2005, Health technology assessment.

[40]  J. Deeks,et al.  A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. , 2005, Health technology assessment.